Global Pseudouridine Market Insights and Forecast to 2028

Pseudouridine, an isomer of uridine (U), is used as a tumor marker to guide the diagnosis, monitoring and efficacy assessment of malignancies such as lung, breast and liver cancers. Although normal mRNA present in vivo has uridine as one of the four nucleic acid compounds in the sequence, mRNA developed as a therapeutic agent or vaccine is made using a modified nucleic acid (pseudouridine) instead of uridine (and other derivatives). Pseudouridine was originally present in the body as a component, such as tRNA (transfer RNA), which is a type of RNA.
Market Analysis and Insights: Global Pseudouridine Market
Due to the COVID-19 pandemic, the global Pseudouridine market size is estimated to be worth US$ 126.1 million in 2022 and is forecast to a readjusted size of US$ 945.4 million by 2028 with a CAGR of 39.9% during the review period. Fully considering the economic change by this health crisis, Powder accounting for % of the Pseudouridine global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Vaccines segment is altered to an % CAGR throughout this forecast period.
In the global market, the core manufacturers of pseudouridine include BOC Sciences and TriLink BioTechnologies (Maravai LifeSciences) etc, and the top 2 manufacturers account for above 60% of the market share. The market include North America, Europe and Asia Pacific, with a share of 52%, 35% and 13%. powder accounted for 72% and solutions accounted for 28%. The product is mainly used in vaccines and scientific research, with a share of 74% and 26%.
Global Pseudouridine Scope and Segment
Pseudouridine market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Pseudouridine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Powder
Solutions
Segment by Application
Vaccines
Scientific Research
By Company
BOC Sciences
YAMASA
TriLink BioTechnologies (Maravai LifeSciences)
Thermo Scientific Chemicals
Biosynth Carbosynth
Wuhan Glycogene
Ulcho Biochemical Ltd (FCAD Group)
Shanghai Hongene Biotech
Wuhan Finetech
MP Biomedicals
Toronto Research Chemical
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Frequently Asked Questions